Printer Friendly

Effects of Saponin from Trigonella Foenum-Graecum Seeds on Dyslipidemia.


Trigonella foenum-graecum, also called fenugreek, has been widely cultivated in the Mediterranean region and Asia for manufacturing spices since ancient times. (1) Its crude extract has been reported to prevent hepatotoxicity (2) and diabetic (3,4) successfully. To evaluate the effects of Trigonella foenum-graecum seeds (TFGs) on cardiovascular disease, studies on the effect of TFGs on dyslipidemia are still to proceed. Etsuko et al. reported TFGs aqueous extract was effective in lowering serum lipid in rats fed with high-fat-diet and accelerated the cholesterol and bile acid efflux. (5) Kumar et al. found that after treating TFGs aqueous extract on high-fat-diet rats, several antioxidant enzymes were elevated and fatty acid synthetase was stored at the normal level. They believe that TFGs modulated dyslipidemia through inhibition of impaired lipid digestion and absorption. (6) Vijayakumar et al. analyzed lowered sterol regulatory element-binding protein-1 (SREBP-1) and elevated low-density lipoprotein (LDL) receptor after treated with aqueous extract in rats fed with high-fat-diet, inferred TFGs had a potential effect on dyslipidemia due to inhibition for lipid accumulation. (7) Taku et al. prepared saponin fraction from TFGs and treated on rats fed with high-fat-diet. They observed lowered serum triglyceride (TG) level. Hence, they proved that diosgenin was the main effective saponin on inhibiting liver X receptor-alpha and SREBP-1c levels in HepG2 cells. (8)

Saponin in TFGs is a promising candidate for ameliorating dyslipidemia. However, most relevant studies on dyslipidemia-modulating activities of TFGs were using aqueous extract. Specific studies about saponin fraction are still required to illustrate its lipid-lowering activities. On the other hand, the definite mechanisms linking saponin to modulating dyslipidemia are not fully understood yet.

In the present study, we prepared high purity saponin extract from TFGs and designed a systematic mechanism study in vivo. We considered four aspects of the mechanisms of dyslipidemia-modulating effects. Firstly, cholesterol absorption from daily diet is mainly depended on Niemann-Pick C1-Like 1 (NPC1L1) and ATP-binding cassette transporters G5/G8 (ABCG5/G8) in the intestine. As a pair of opposing gatekeeper, NPC1L1 and ABCG5/ABCG8 control cholesterol intake and outflow in the small intestine, respectively. (9) Secondly, extrahepatic cholesterol returns to the liver for excretion to the bile and ultimately to the feces, which is known as the process of reverse cholesterol transport (RCT). The RCT process is mainly performed by two crucial cellular factors, transporter (ATP-binding cassette transporter member A1 (ABCA1) and receptor (scavenger receptor class B type I (SR-BI)). ABCA1 is abundantly expressed in both the liver and peripheral macrophages among other tissues. (10,11) Cellular cholesterol and phospholipids can be efflux and transformed into high-density lipoprotein (HDL), mediated by ABCA1. Thus, HDL finally combines mainly with SR-BI, a high specific receptor of HDL. (11) Thirdly, serum lipid is mainly from synthesis of cholesterol and triglyceride in vivo are corresponding to 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoAR) and sterol regulatory element-binding proteins-1c (SREBP-1c) expressions, respectively. (8,12) Finally, cholesterol is transformed into bile acid and efflux outside of the body, which is also an important cholesterol-eliminating way and the transformation is mainly controlled by cholesterol 7alpha-hydroxylase (CYP7A1). (13)

With great appreciation of fundamental contributions by other researchers, we further extracted and purified saponin from TFGs, investigated its dyslipidemia-modulating activities in obese rats' models, and systematically illustrated their lipid-lowering mechanisms.

Materials and Methods

Extraction and Purification of Saponin from TFGs

TFGs were provided by Bozhou-ShuZhong Chinese herbal medicine industry Ltd., China. Diosgenin was extracted and purified as reported previously. (14) All steps were completed at the Key Lab of Hui Ethnic Medicine Modernization, Ministry of Education (Ningxia, China). Briefly, TFGs were extracted by 75% (v/v) ethanol with material-liquid ratio of 1:12 (w/v) three times (1.5, 1, and 0.5 hours, respectively) at 75 [degrees]C. The liquid extract was then concentrated by vacuum distillation and freeze-dried ground. The powdered extract was then dealt with different solvents systematically, including n-hexane, chloroform, ethyl acetate, and n-buthanol. Chloroform fraction was dried and further purified through HPD-400 macroreticular resins. The purity of saponin in the final dry product was determined by ultraviolet spectroscopy and reached 80.50%. Hence, the final product was used in the present study.


The present study was conducted in conformity with the PHS policy on Use of Laboratory Animals and WMA Declaration of Helsinki, as well as approval and authorization by the Animal Ethical Committee of Ningxia Medical University (Ningxia, China). Four-week-old male Sprague-Dawley rats of specific pathogen-free level were recruited from the Laboratory Animal Center of Ningxia Medical University (License number: SCXY (Ning) 2005-0001). All rats were housed in a temperature-controlled room (22[+ or -]1 [degrees]C) with a 12-h light cycle (6 am to 6 pm) and 12-h dark cycle (6 pm to 6 am) and kept three per cage.

After 1-week adapting period, 40 male rats were given high-fat-diet (HFD) as the model group, and 8 other rats were given a normal diet (ND) every day as the control group. Both groups were fed with 18.5 g HFD or ND (D12451 and GB13078, respectively) (Beijing Keaoxieli Ltd., China) on a daily basis. After 4 weeks, TC and TG levels of blood from the eye fundus were tested. Then, the model group was divided into five subgroups and treated in different conditions daily; the HFD group (HFD plus normal saline (NS)), Lipitor group (HFD with 10 mg/kg Lipitor, oral administration), and L-saponin, M-saponin, and H-saponin groups (oral administration, HFD with 6, 12, and 24 mg/kg saponin, respectively). Initially, the groups were almost of identical average weight and activity. The control group started to be irrigated with normal saline. All rats were further treated for 9 weeks and the dosages of Lipitor or saponin was weekly adjusted according to individual weight. In the 9th week, feces of rats in each group were collected and kept in -20 [degrees]C for further study. At the end of the experiment, after fasting for 24 h, all rats were anesthetized with chloral hydrate injection in the abdomen cavity and sacrificed. Livers and intestines were separated, immediately froze by liquid nitrogen and kept in -70[degrees]C for further measurement.

Morphological Observation

Food consumption was monitored every day. The weight of all rats was determined every 7 days. Liver weights were measured as soon as they were separated out and the liver index was used as a morphological parameter.

Liver index=(liver weight/body weight)x100%

Blood Sample Assays

Blood from femoral artery was collected and serum was separated by centrifugation for 15 minutes at 4,000 rpm and stored at -20 [degrees]C. Serum malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), and HMG-COAR levels were determined by each kit. All procedures were performed according to the manufacturers' instructions. TC, TG, LDL, HDL, glutamic-pyruvic transaminase (ALT), and glutamic oxalacetic transaminase (AST) levels were determined at the Biochemistry Study Institution, Affiliated Hospital of Ningxia Medical University (Ningxia, China). Total cholesterol (TC), total glyceride (TG), SOD, and MDA kits were from Nanjing Jiancheng Bioengineering Research Institute, China. HMG-CoA reductase kit was procured from Beijing Chenglin Biotechnology Ltd., China. GSH-PX kit was obtained from Beijing Yonghui Biotechnology Ltd., China.

Feces Assays

Before the end of treatment, feces in each cage were collected for seven days. Cholesterol and bile acid were extracted according to Carr's method. (15) Briefly, after lyophilization, 5 g feces was added into 100 mL mixture of 66.7 mL chloroform and 33.3 mL methanol, shook thoroughly for 3 minutes and filtrated through degreased filter paper. The filtrated mixture was then mixed with 20 mL 0.05% sulfuric acid in a separating funnel for 20 minutes and the lower layer was collected. One-milliliter liquid in lower layer was mixed with 1 mL 1% TritonX-100 and then dried at 45[degrees]C. Total cholesterol (TC) and total bile acid (TBA) levels were tested by each kit (Nanjing Jiancheng Bioengineering Research Institute, China). All procedures were performed according to the manufacturer's instructions. The output of cholesterol and bile acid was expressed as mmol cholesterol (or bile acid) per gram feces.

Histopathological Assay

Hepatic lobule from fresh liver was taken and fabricated into histopathological sections through hematoxylin-eosin staining. It was then observed by the Pathodology Department, Affiliated Hospital of Ningxia Medical University (Ningxia, China).

Western Blotting

About 50 [mu]g frozen intestine was ground with liquid nitrogen and the total protein was extracted by a protein extracting kit (KeyGEN Whole Cell Lysis Assay, KeyGEN BioTECH Ltd. China.) according to the manufacturer's description. The supernatant was collected by centrifugation for 5 minutes at 10,000 rpm. After quantification using a protein quantification kit (KeyGEN BCA Protein Quantitation Assay, KeyGEN BioTECH Ltd. China) according to the manufacturer's description, the protein of each group was diluted into almost the same concentration (5 [mu]g/[mu]L). Total protein (~80 [mu]g) from each specimen was loaded onto 8% SDS-PAGE.After electrophoresis at 80V~120V for 80 minutes, fractionated proteins were transferred to pure nitrocellulose blotting membrane (Pall Gelman Laboratory, USA) at 200 mA for 2 hours. Membranes were cut into strips and blocked by 5% skim milk for 1 hour before incubating with Anti-ABCG8 antibody (sc-30111, Santa Cruz Ltd.), Anti-NPC1L1 antibody (TA309769, Origene Ltd.), and mouse anti-beta actin antibody monoclonal antibody (ZSGB-BIO Ltd.) at 4 [degrees]C overnight. The strips were subjected to 10 minutes washing 3 times with PBS containing 0.05% Tween 20. This procedure was followed by incubation with peroxidase-conjugated affinipure goat anti-rabbit IgG (H+L) or peroxidase-conjugated affinipure goat anti-mouse IgG (H+L) (ZSGB-BIO Ltd.) for 2 hours, and by 5 minutes washing 6 times. The strips were immersed in Lu-Mino substrate buffer and gently shaken. After exposure and fixing, protein bands were semi-quantitatively analyzed by the QuantityOne software.

Quantitative Real-Time RT-PCR

RNA was prepared from rats' tissues using a total RNA isolation kit (AxyPrep Multisource Total RNA Miniprep Kit, Corning Incorporated (Wujiang), China.) according to the manufacturer's instructions. Total RNA was reverse transcribed using a total RNA reverse transcription kit (One-Step gDNA Removal and cDNA Synthesis SuperMix, Beijing TransGen Biotech Co., Ltd., China). The cDNA was used as a template for quantitative real-time RT-PCR using Tip Green qPCR SuperMix. To select the optimal primer and annealing temperature for each gene, three pairs of primers were designed. Before qRT-PCR, cDNA templates were dealt with amplification in gradient temperature with each primer and the optimal conditions were selected after electrophoresis and were further validated by analyzing amplification curve and melt curve. The selected optimal primers are shown in table 1. The relative mRNA expression of each group versus HFD group is expressed with [2.sup.-[DELTA][DELTA]Ct] after qRT-PCR. (16)

Statistics Analyses

All analyses were performed using the SPSS software version 11.5 (SPSS, Chicago, IL, USA). One-way ANOVA test was used to determine statistically significant differences between the HFD and other groups. P values less than 0.05 were considered significant and P values less than 0.01 were considered extremely significant.


Establishment of Dyslipidemia Rat Model

After one-month HFD feeding, TC and TG in serum were observed slightly and significantly higher in the HFD group than the control group, respectively (1.61, 0.69 mmol/L vs. 1.45, 0.46 mmol/L, P=0.490 and 0.023, data not shown).

Biochemical Characteristics of Rats

Dyslipidemia rat model was divided into different groups as described above. After being sacrificed, the total body weight, gained weight after treating, liver index, serum lipid levels, ALT and AST levels, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX) levels, HMG-CoAR levels in serum, cholesterol (TC) and total bile acid (TBA) levels in feces were tested (table 2).

Histopathological Sections of the Liver Tissue

Figure 1 shows the histopathological morphology of the liver tissue of each group after stained with H&E. Restored lipid areas in the liver tissue were observed in saponin groups and showed a dose-dependent tendency.

Protein and mRNA Expression of Related Factors of Cholesterol

Figure 2 shows NPC1L1 and ABCG8 protein expression in the intestine detected by Western blot method as described. Figure 3 shows CYP7A1, ABCG8, NPC1L1, HMG-CoAR, SREBP-1c, ABCA1, and SR-BI mRNA levels in the liver determined by qRT-PCR.


Saponin is the main effective ingredient from fenugreek on modulating dyslipidemia. (8,17,18) In this article, we further confirmed the effectiveness of fenugreek saponin on dyslipidemia and explored possible mechanisms. Saponin was effective in modulating serum lipid, although not apparently influenced the weight in rats fed with HFD. There was no significant difference in the food intake and water intake during the experiment. Saponin could not successfully decrease the abnormal weight of rats fed with HFD, but it modulated serum lipid levels by decreasing TC, TG, LDL levels and elevated HDL levels (table 2). Consistent with the present study, the extract of TFGs is reported to decrease serum lipid in diabetic rabbits, (19) patients, (18) and rats. (20) Different from other studies on water extract of trigonella foenum-graecum seeds (e.g. Mohammadi et al. and Kumar et al. (21-23)), the saponin extract made impact on the weight gain of the rats in our study. Considering lowered liver index in the saponin groups, we presumed that saponin could also restore liver tissue of rats fed with HFD.

Saponin also restored liver tissue and elevated anti-peroxidation activities in vivo. Rats of dyslipidemia were also benefited from fanugreek saponin in two auxiliary aspects; restored liver tissue and elevated anti-peroxidation activities. Saponin lowered abnormal serum ALT levels (table 2) and eliminated lipid areas in the liver tissue (figure 1) of rats fed with HFD. This finding was consistent with those by Parveen Kumar et al.6 On the other hand, accompanying dyslipidemia, peroxidation probably induces atherosclerosis which endangers the cardiovascular system. (25) Elevated MDA level and lowered SOD level indicated that HFD might aggravate dyslipidemia by inducing peroxidation. Saponin treatment could obviously elevate serum SOD levels in rats fed with HFD. Restored SOD levels in serum can be found after healing with saponin (table 2). This result can also be supported by the study of Belguith-Hadriche et al. that used ethyl acetate extract of fenugreek (25) and studies on diosgenin, the main saponin in fenugreek. (26,27)

Saponin might not eliminate serum lipid through reducing cholesterol absorption in the intestine. Based on the above results, mechanisms and pathways oflipid-lowering effect were further studied. With respect to cholesterol absorption and efflux, previous reports (5,28) have shown that water extracts of TFGs could accelerate the outputting of TC and TBA into feces. In our study, saponin dose-dependently increased TBA level but showed no obvious influences on the TC level in feces (table 2). This is possibly due to using saponin ingredient, but not the whole water extract. Being a pair of gatekeeper, which control cholesterol intake and efflux of intestinal cells, NPC1L1 and ABCG8 (9) were employed to explain the performance of TC and TBA efflux. The Western blot results showed saponin treatment induced higher NPC1L1 protein express and no obvious change on ABCG8 (figure 2). This means that cholesterol absorption in the intestine was facilitated without influencing its excretion. Tang et al. (29) reported that the final excretion of cholesterol was strongly correlated with the expression of NPC1L1 in the intestine. In the present study, no change of excretion of cholesterol was observed, although the expression of NPC1L1 in the intestine was elevated. Where did the absorbed cholesterol go and why the excretion of total bile acid increased? In this regard, we further studied the effect of cholesterol metabolism.

Saponin probably accelerates TBA efflux through facilitating cholesterol metabolism involve with RCT. Considering the above observation, we presumed that excess TBA in feces correlated with cholesterol metabolism. To confirm the up-regulatory activity of saponin for cholesterol metabolism, we tested the CYP7A1, ABCG8, and NPC1L1 levels in the liver by qRTPCR. CYP7A1 is the rate-limiting enzyme in the bile acid biosynthetic pathway in the liver and thus controls cholesterol and bile acid homeostasis. ABCG8 and NPC1L1 influence the rate of cholesterol metabolism by accelerating and inhibiting, respectively. (9,13) Under the dual function of elevated NPC1L1 in the intestine and CYP7A1 in the liver (figures 2 and 3A), both the cholesterol absorption and metabolism were simultaneously facilitated. That explained why TBA level in feces was obviously elevated, whereas TC level had no significant change.

Besides, RCT can also facilitate cholesterol metabolism and it is the most important way to eliminate peripheral cholesterol. (10) This process involves two main factors, namely ABCA1 and SR-BI. ABCA1 mRNA expression in the liver was dose-dependently increased in saponin-treated groups (figure 3B), which is probably the main reason for elevated HDL level in the serum of saponin groups (table 2). However, there were no significant changes in SR-BI mRNA expression. These results revealed that highdose saponin might partly facilitate RCT process by escalating ABCA1 mRNA expression. As a result, excess TBA levels in feces of rats treated with saponin might mainly be a response to cholesterol metabolism.

Diongenin could also inhibit cholesterol synthesis in vivo. Saponin also contributes to modulate serum lipid through inhibiting cholesterol synthesis in vivo, but it might induce excess triglyceride synthesis in high dosage. The synthesis processes of cholesterol and triglyceride, as the main sources of serum TC and TG, are characterized by HMG-CoAR and SREBP-1c, respectively. HMG-CoAR activity in serum (table 2) and mRNA expression in the liver (figure 3C) were decreased for all saponin-treated groups. This result is also supported by a study focused on HMG-CoAR inhibiting effect of diosgenin by Hao et al. (30) However, SREBP-1c mRNA expression in the liver elevated when high-dose saponin was treated (figure 3C). This was in contrast to a similar study that fed KK-Ay mice with the crude extract of TFGs and treated HepG2 cells with diogenin. (8) Perhaps such discrepancy is due to different ingredients used. Hence, fenugreek saponin can suppress cholesterol synthesis, but it might accelerate the synthesis of triglyceride under high-dose treatment.


For the first time, the present study demonstrates that saponin from TFGs can effectively accelerate cholesterol metabolism and RCT process, meanwhile inhibit cholesterol synthesis. This multi-pathway action of fanugreek saponin on ameliorating dyslipidemia is preferable in preventing cardiovascular disease effectively.


The authors would like to thank Pathodology Department and Biochemistry Study Institution (Affiliated Hospital of Ningxia Medical University) for supporting the present study. This research was also supported by grants from the Animal Ethical Committee of Ningxia Medical University and National Science Foundations of China. Zhi Chen and Yan-li Lei contributed equally to this work.

Conflict of Interest: None declared.


(1.) Mehrafarin A, Rezazadeh Sh, Naghdi Badi H, Noormohammadi Gh, Zand E, Qaderi A. A Review on Biology, Cultivation and Biotechnology of Fenugreek (Trigonella foenum-graecum L.) as a Valuable Medicinal Plant and Multipurpose. Journal of Medicinal Plants. 2011;10:6-24. doi: 10.4172/2157-7110.1000181.

(2.) Sushma N, Devasena T. Aqueous extract of Trigonella foenum graecum (fenugreek) prevents cypermethrin-induced hepatotoxicity and nephrotoxicity. Hum Exp Toxicol. 2010;29:311-9. doi: 10.1177/0960327110361502. PubMed PMID: 20147568.

(3.) Haeri MR, Limaki HK, White CJ, White KN. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine. 2012;19:571-4. doi: 10.1016/j.phymed.2012.01.004. PubMed PMID: 22397995.

(4.) Hamza N, Berke B, Cheze C, Le Garrec R, Umar A, Agli AN, et al. Preventive and curative effect of Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet. J Ethnopharmacol. 2012;142:516-22. doi: 10.1016/j.jep.2012.05.028. PubMed PMID: 22633967.

(5.) Muraki E, Matsuoka C, Oikawa R, Sato S, Chiba H, Tsunoda N, et al. Fenugreek attenuates lipid accumulation in normal rats. J Jpn Nutr Food Sci. 2011;64:99-106. doi: 10.4327/jsnfs.64.99.

(6.) Kumar P, Bhandari U, Jamadagni S. Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats. Biomed Res Int. 2014;2014:606021. doi: 10.1155/2014/606021. PubMed PMID: 24868532; PubMed Central PMCID: PMC4020548.

(7.) Vijayakumar MV, Pandey V, Mishra GC, Bhat MK. Hypolipidemic effect of fenugreek seeds is mediated through inhibition of fat accumulation and upregulation of LDL receptor. Obesity (Silver Spring). 2010;18:667-74. doi: 10.1038/oby.2009.337. PubMed PMID: 19851306.

(8.) Uemura T, Goto T, Kang MS, Mizoguchi N, Hirai S, Lee JY, et al. Diosgenin, the main aglycon of fenugreek, inhibits LXRalpha activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. J Nutr. 2011;141:17-23. doi: 10.3945/jn.110.125591. PubMed PMID: 21106928.

(9.) Brown JM, Yu L. Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8). Immunol Endocr Metab Agents Med Chem. 2009;9:18-29. doi: 10.2174/187152209788009797. PubMed PMID: 20174593; PubMed Central PMCID: PMC2824437.

(10.) Xu Y, Liu Q, Xu Y, Liu C, Wang X, He X, et al. Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT. J Lipid Res. 2014;55:1634-47. doi: 10.1194/jlr.M044198. PubMed PMID: 24908654; PubMed Central PMCID: PMC4109758.

(11.) Sporstol M, Mousavi SA, Eskild W, Roos N, Berg T. ABCA1, ABCG1 and SR-BI: hormonal regulation in primary rat hepatocytes and human cell lines. BMC Mol Biol. 2007;8:5. doi: 10.1186/1471-2199-8-5. PubMed PMID: 17241464; PubMed Central PMCID: PMC1790708.

(12.) Canovas A, Quintanilla R, Gallardo D, Diaz I, Noguera JL, Ramirez O, et al. Functional and association studies on the pig HMGCR gene, a cholesterol-synthesis limiting enzyme. Animal. 2010;4:224-33. doi: 10.1017/S1751731109991145. PubMed PMID: 22443876.

(13.) Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G, et al. Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011;53:996-1006. doi: 10.1002/hep.24107. PubMed PMID: 21319191; PubMed Central PMCID: PMC3079544.

(14.) Hei J, Chen Z, Lei Y, Wang W, Sui H. Investigation of Extraction and Purification Process for Total Saponins in Trigonellae Semen. Chinese Journal of Experimental Traditional Medical Formulae. 2014;20:11-3.

(15.) Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem. 1993;26:39-42. PubMed PMID: 8448837.

(16.) Yuan JS, Reed A, Chen F, Stewart CN, Jr. Statistical analysis of real-time PCR data. BMC Bioinformatics. 2006;7:85. doi: 10.1186/1471-2105-7-85. PubMed PMID: 16504059; PubMed Central PMCID: PMC1395339.

(17.) Fuller S, Stephens JM. Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv Nutr. 2015;6:189-97. doi: 10.3945/an.114.007807. PubMed PMID: 25770257; PubMed Central PMCID: PMC4352177.

(18.) Verma N, Usman K, Patel N, Jain A, Dhakre S, Swaroop A, et al. A multicenter clinical study to determine the efficacy of a novel fenugreek seed (Trigonella foenum-graecum) extract (Fenfuro) in patients with type 2 diabetes. Food Nutr Res. 2016;60:32382. doi: 10.3402/fnr.v60.32382. PubMed PMID: 27733237; PubMed Central PMCID: PMC5061863.

(19.) Puri D, Prabhu KM, Dev G, Agarwal S, Murthy PS. Mechanism of Antidiabetic Action of Compound GII Purified from Fenugreek (Trigonella foenum graecum) Seeds. Indian J Clin Biochem. 2011;26:335-46. doi: 10.1007/s12291-011-0150-2. PubMed PMID: 23024468; PubMed Central PMCID: PMC3210251.

(20.) Haritha C, Reddy AG, Reddy YR, Anilkumar B. Pharmacodynamic interaction of fenugreek, insulin and glimepiride on sero-biochemical parameters in diabetic Sprague-Dawley rats. Vet World. 2015;8:656-63. doi: 10.14202/vetworld.2015.656-663. PubMed PMID: 27047152; PubMed Central PMCID: PMC4774730.

(21.) Mohammadi A, Gholamhosseinian A, Fallah H. Trigonella foenum-graecum water extract improves insulin sensitivity and stimulates PPAR and gamma gene expression in high fructose-fed insulin-resistant rats. Adv Biomed Res. 2016;5:54. doi: 10.4103/2277-9175.178799. PubMed PMID: 27110551; PubMed Central PMCID: PMC4817393.

(22.) Kumar P, Kale RK, McLean P, Baquer NZ. Antidiabetic and neuroprotective effects of Trigonella foenum-graecum seed powder in diabetic rat brain. Prague Med Rep. 2012;113:33-43. doi: 10.14712/23362936.2015.35. PubMed PMID: 22373803.

(23.) Kumar P, Kale RK, Baquer NZ. Antihyperglycemic and protective effects of Trigonella foenum graecum seed powder on biochemical alterations in alloxan diabetic rats. Eur Rev Med Pharmacol Sci. 2012;16 Suppl 3:18-27. PubMed PMID: 22957414.

(24.) Ramulu P, Giridharan NV, Udayasekhararao P. Hypolipidemic effect of soluble dietary fiber (galactomannan) isolated from fenugreek seeds in WNIN (GR-Ob) obese rats. J Med Plant Res. 2011;5:4804-13.

(25.) Belguith-HadricheO, Bouaziz M, Jamoussi K, El Feki A, Sayadi S, Makni-Ayedi F. Lipid-lowering and antioxidant effects of an ethyl acetate extract of fenugreek seeds in high-cholesterol-fed rats. J Agric Food Chem. 2010;58:2116-22. doi: 10.1021/jf903186w. PubMed PMID: 20108903.

(26.) Kalailingam P, Kannaian B, Tamilmani E, Kaliaperumal R. Efficacy of natural diosgenin on cardiovascular risk, insulin secretion, and beta cells in streptozotocin (STZ)-induced diabetic rats. Phytomedicine. 2014;21:1154-61. doi: 10.1016/j.phymed.2014.04.005. PubMed PMID: 24889525.

(27.) Son IS, Kim JH, Sohn HY, Son KH, Kim JS, Kwon CS. Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem. 2007;71:3063-71. doi: 10.1271/bbb.70472. PubMed PMID: 18071250.

(28.) Prajapati VD, Jani GK, Moradiya NG, Randeria NP, Nagar BJ, Naikwadi NN, et al. Galactomannan: a versatile biodegradable seed polysaccharide. Int J Biol Macromol. 2013;60:83-92. doi: 10.1016/j.ijbiomac.2013.05.017. PubMed PMID: 23707734.

(29.) Tang W, Jia L, Ma Y, Xie P, Haywood J, Dawson PA, et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochim Biophys Acta. 2011;1811:549-55. doi: 10.1016/j.bbalip.2011.05.013. PubMed PMID: 21683156; PubMed Central PMCID: PMC3140631.

(30.) Hao S, Xu R, Li D, Zhu Z, Wang T, Liu K. Attenuation of Streptozotocin-Induced Lipid Profile Anomalies in the Heart, Brain, and mRNA Expression of HMG-CoA Reductase by Diosgenin in Rats. Cell Biochem Biophys. 2015;72:741-9. doi: 10.1007/s12013-015-0525-8. PubMed PMID: 25631375.

Zhi Chen (1,2), M-Phil, MD;

Yan-Li Lei (2), MD;

Wen-Ping Wang (2,3,4), PhD;

Ya-Ya Lei (2,5), MD;

Yan-Hua Liu (2,3,4), PhD;

Jing Hei (2,5), MD;

Jin Hu (2,5), MD

Hong Sui (2,3,4), PhD

(1) Faculty of Medicine, Shimane University, Shimane, Japan;

(2) School of Pharmacy, Ningxia Medical University, Yinchuan Ningxia, China;

(3) Ningxia Engineering and Technology Research Center, Modernization of Hui Medicine, Yinchuan Ningxia, China;

(4) Key Lab of Hui Ethnic Medicine Modernization, Ministry of Education, Yinchuan Ningxia, China;

(5) General Hospital of Ningxia Medical University, Yinchuan Ningxia, China


Hong Sui, PhD; School of Pharmacy, Ningxia Medical University, Yinchuan Ningxia 750001, China

Tel: +86 139 95113086

Fax: +86 951 6880693


Received: 23 August 2016

Revised: 17 October 2016

Accepted: 13 November 2016

What's Known

* Trigonella foenum-graecum seeds can ameliorate dyslipidemia, and saponins may constitute one of the most effective ingredients.

* Mechanism may be related to accelerating cholesterol and bile acid efflux and suppressing the expression of SREBP-1 in the liver.

What's New

* Mechanisms of dyslipidemia-ameliorating effects of saponins from Trigonella foenum-graecum seeds were firstly explicated through accelerating cholesterol metabolism and reverse cholesterol transport and inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase in both serum and liver.
Table 1: Designed primers of each gene for qRT-PCR. Optimized primers
and annealing temperatures for each gene with different product size

Gene          Primer (5'-3')                  Annealing temperature (C)

              Reverse  TCCATCTCTTGGCTGCTCTC
              Reverse  GTGCGATCTTCCCATTCAGT
              Reverse  CAGAAGCCAGCAAACACTTG
              Reverse  CCAAAGGAGCCCATAAATGA
ABCG8         Forward  CCTTCGTTTCCAGCCAGAC    60
              Reverse  CTTGTCCTCCATCATCACTGC
              Reverse  CCTCCTTAGCTGTGCGGATA
[beta]-actin  Forward  CCCATCTATGAGGGTTACGC   60
              Reverse  TTTAATGTCACGCACGATTTC

Gene          Product size (bp)

HMG-CoAR      103
CYP7A1        122
SREBP-1c      105
ABCA1         106
ABCG8         100
SR-BI         118
[beta]-actin  150

Table 2: Biochemical characteristics of rats according to different
groups. Data are reported as mean[+ or -]SD of eight rats carried out
in duplicate

Groups                  Control                    HFD

Liver index              2.03%[+ or -]0.06% (*)     2.18%[+ or -]0.13%
Final weight (g)       450[+ or -]43 (**)         576[+ or -]37
Gained weight (g)       77[+ or -]19 (*)          113[+ or -]28
TC (mmol/L)              1.449[+ or -]0.071 (**)    1.831[+ or -]0.176
TG (mmol/L)              0.455[+ or -]0.040 (**)    0.755[+ or -]0.240
LDL (mmol/L)             0.150[+ or -]0.022 (**)    0.288[+ or -]0.055
HDL (mmol/L)             1.430[+ or -]0.126 (**)    0.934[+ or -]0.300
ALT (U/L)               35.525[+ or -]4.362 (**)   73.850[+ or -]28.292
AST (U/L)               88.925[+ or -]20.541      109.150[+ or -]16.449
MDA (nmol/L)             1.600[+ or -]0.289         2.500[+ or -]0.367
SOD (U/L)              243.939[+ or -]14.979 (*)  222.479[+ or -]11.844
GSH-PX (mmol/L)         20.111[+ or -]0.008        20.080[+ or -]0.073
HMG-COAR (U/L)          19.219[+ or -]0.335        19.007[+ or -]0.501
TC in                    1.412[+ or -]0.090 (*)     1.206[+ or -]0.042
feces ([micro]mol/g)
TBA in                  2.380[+ or -]0.338 (**)    3.586[+ or -]0.259
feces ([micro]mol/g)

Groups                   Lipitor

Liver index              2.06%[+ or -]0.18% (*)
Final weight (g)       532[+ or -]77
Gained weight (g)       93[+ or -]45
TC (mmol/L)              1.364[+ or -]0.180 (**)
TG (mmol/L)              0.576[+ or -]0.192 (**)
LDL (mmol/L)             0.186[+ or -]0.039 (**)
HDL (mmol/L)             1.159[+ or -]0.103 (*)
ALT (U/L)               46.263[+ or -]6.901 (**)
AST (U/L)              107.438[+ or -]24.674
MDA (nmol/L)             2.266[+ or -]1.004
SOD (U/L)              232.619[+ or -]17.457
GSH-PX (mmol/L)         20.110[+ or -]0.005
HMG-COAR (U/L)          18.854[+ or -]0.445
TC in                    0.993[+ or -]0.117 (*)
feces ([micro]mol/g)
TBA in                   3.422[+ or -]0.230
feces ([micro]mol/g)

Groups                     L-saponin

Liver index                2.07%[+ or -]0.09%
Final weight (g)         568[+ or -]65
Gained weight (g)        123[+ or -]32
TC (mmol/L)                1.506[+ or -]0.150 (**)
TG (mmol/L)                0.616[+ or -]0.063 (*)
LDL (mmol/L)               0.249[+ or -]0.047
HDL (mmol/L)               1.009[+ or -]0.178
ALT (U/L)                 54.088[+ or -]14.198(**)
AST (U/L)                 90.150[+ or -]10.144
MDA (nmol/L)               2.414[+ or -]0.512
SOD (U/L)                230.798[+ or -]23.572
GSH-PX (mmol/L)           20.020[+ or -]0.135
HMG-COAR (U/L)            18.306[+ or -]0.261 (**)
TC in                      1.113[+ or -]0.103
feces ([micro]mol/g)
TBA in                     3.679[+ or -]0.118
feces ([micro]mol/g)

Groups                   M-saponin

Liver index                2.07%[+ or -]0.09%
Final weight (g)             579[+ or -]56
Gained weight (g)            128[+ or -]25
TC (mmol/L)                1.499[+ or -]0.299 (**)
TG (mmol/L)                0.573[+ or -]0.155 (**)
LDL (mmol/L)               0.254[+ or -]0.058
HDL (mmol/L)               1.195[+ or -]0.274 (**)
ALT (U/L)                 38.788[+ or -]16.593 (**)
AST (U/L)                 97.113[+ or -]21.672
MDA (nmol/L)               2.460[+ or -]0.301
SOD (U/L)                247.445[+ or -]27.572 (**)
GSH-PX (mmol/L)           20.114[+ or -]0.007
HMG-COAR (U/L)            17.628[+ or -]0.540 (**)
TC in                      1.193[+ or -]0.099
feces ([micro]mol/g)
TBA in                     4.333[+ or -]0.205 (**)
feces ([micro]mol/g)

Groups                  H-saponin

Liver index               2.06%[+ or -]0.07% (*)
Final weight (g)            581[+ or -]68
Gained weight (g)           127[+ or -]58
TC (mmol/L)               1.528[+ or -]0.171(**)
TG (mmol/L)               0.581[+ or -]0.090(**)
LDL (mmol/L)              0.213[+ or -]0.047(**)
HDL (mmol/L)              1.186[+ or -]0.108(**)
ALT (U/L)                36.063[+ or -]8.772(**)
AST (U/L)               100.925[+ or -]16.595
MDA (nmol/L)              2.400[+ or -]1.065
SOD (U/L)               241.753[+ or -]22.158(*)
GSH-PX (mmol/L)          20.093[+ or -]0.046
HMG-COAR (U/L)           17.698[+ or -]0.826(**)
TC in                     1.173[+ or -]0.181
feces ([micro]mol/g)
TBA in                    5.253[+ or -]0.096(**)
feces ([micro]mol/g)

P values are obtained from the independent sample t-test between two
groups (HFD group and another group). (*) P<0.05: Indicate
significant difference from the HFD group; (**) P<0.01: Indicate
extremely significant difference from the HFD group; ALT:
Glutamic-pyruvic transaminase; AST: Aspartate transaminase; GSH-PX:
Glutathione peroxidase; HFD: High-fat-diet; HMG-CoAR:
3-hydroxy-3-methyl glutaryl coenzyme A reductase; MDA:
Malondialdehyde; TBA: Total bile acid; TC: Total cholesterol;
TG: Triglyceride
COPYRIGHT 2017 Shiraz University of Medical Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article
Author:Chen, Zhi; Lei, Yan-Li; Wang, Wen-Ping; Lei, Ya-Ya; Liu, Yan-Hua; Hei, Jing; Hu, Jin; Sui, Hong
Publication:Iranian Journal of Medical Sciences
Article Type:Report
Date:Nov 1, 2017
Previous Article:Long-term Low-Intensity Endurance Exercise along with Blood-Flow Restriction Improves Muscle Mass and Neuromuscular Junction Compartments in Old Rats.
Next Article:Deltamethrin-Induced Hepatotoxicity and Virgin Olive Oil Consumption: An Experimental Study.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |